Combination Treatment for PTSD After the WTC Attack
世贸中心袭击后 PTSD 的联合治疗
基本信息
- 批准号:7426931
- 负责人:
- 金额:$ 43.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-04-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:AccidentsAcuteAdultAirAnthrax diseaseAnxietyAreaBehavior TherapyCharacteristicsChronicClinicalClinical TrialsCombination MedicationCommunitiesComorbidityComplexConditionConflict (Psychology)ConsensusControlled StudyDataDisastersDiseaseDomestic ViolenceDouble-Blind MethodExposure toFamily memberForcible intercourseFrightGoalsGrantGrief reactionIndividualKnowledgeMaintenanceMarshalMeasuresMental DepressionMental disordersMiddle EastNew YorkNumbersParoxetineParticipantPatientsPersonsPharmaceutical PreparationsPhasePlacebosPopulationPost-Traumatic Stress DisordersProceduresPsychopathologyPsychotherapyPublic HealthQuality of lifeRandomizedRateRecommendationRefugeesResearchScheduleScoreSelective Serotonin Reuptake InhibitorSensitivity and SpecificitySeveritiesSilverSubwaySurveysSymptomsSyndromeTerrorismTestingTraumaTravelTreatment outcomeViolenceWarWeekWorkacute stressacute traumatic stress disorderautomobile accidentbaseblindcapsuleclinically significantcostdaydepressive symptomsdesigndisabilityexperienceimprovednovelpillpsychosocialresponsestress related disorder
项目摘要
DESCRIPTION (provided by applicant): Posttraumatic Stress Disorder (PTSD) is a prevalent condition with high rates of disability and comorbidity. Recent surveys in the greater New York area suggest that there still thousands of 9/11-related cases of PTSD due to the severe exposure to the World Trade Center Attack. Previous research has shown that both behavior therapy (prolonged exposure) and, more recently, serotonin reuptake inhibitors (SSRIs), are effective for highly chronic PTSD. However, very little is known about treatment response in individuals with PTSD due to a terrorist act of this scale. In addition, no study has specifically examined the combination of these treatments in individuals with PTSD. Controlled trials from both behavior therapy and medication studies suggest that a substantial proportion of individuals with chronic PTSD benefit from treatment but remain symptomatic and functionally impaired. There are no studies to date that systematically investigate the combination of medication treatment with behavior therapy, although this approach is widely recommended in clinical practice. This study would therefore examine the value of providing SSRI treatment simultaneously with behavior therapy. The overarching goal is the study of maximization of treatment response for adults with chronic PTSD.
Participants will be 100 adults with World Trade Center Attack related PTSD. All patients will be randomly assigned to receive either 10 sessions of exposure therapy plus paroxetine, or 10 sessions of exposure therapy plus placebo. Major assessments by an independent evaluator blind to randomization status will be conducted at baseline, week 5, and week 10. Responders to treatment will be continued on pill/placebo for an additional 12 weeks with assessments at week 14, week 18, and week 22. Assessments will focus on PTSD symptoms, general functioning, interpersonal problems, and comorbid anxiety and depressive symptoms.
This study possesses several strengths. It examines the combination of two cost-effective, validated, complementary treatments in a new population with chronic PTSD (victims of a large scale terrorist attack). It then examines whether benefits remain or even continue to accrue through a maintenance phase. Findings may enhance public health through the study of maximization of treatment response for this serious and common psychiatric disorder.
描述(由申请人提供):创伤后应激障碍 (PTSD) 是一种普遍存在的疾病,其致残和合并症的发生率很高。最近在大纽约地区的调查表明,由于世贸中心袭击事件的严重影响,仍有数千起与 9/11 相关的创伤后应激障碍 (PTSD) 病例。先前的研究表明,行为疗法(长期暴露)和最近的血清素再摄取抑制剂(SSRI)对高度慢性 PTSD 有效。然而,由于如此规模的恐怖行为,人们对创伤后应激障碍患者的治疗反应知之甚少。此外,还没有研究专门检验这些治疗方法对 PTSD 患者的联合作用。行为疗法和药物研究的对照试验表明,相当一部分慢性创伤后应激障碍患者从治疗中受益,但仍然存在症状和功能受损。迄今为止,还没有研究系统地研究药物治疗与行为疗法的结合,尽管这种方法在临床实践中被广泛推荐。因此,本研究将探讨同时提供 SSRI 治疗和行为疗法的价值。总体目标是研究慢性创伤后应激障碍 (PTSD) 成人治疗反应的最大化。
参与者将是 100 名患有世贸中心袭击相关 PTSD 的成年人。所有患者将被随机分配接受 10 次暴露疗法加帕罗西汀,或 10 次暴露疗法加安慰剂。不知道随机化状态的独立评估员将在基线、第 5 周和第 10 周进行主要评估。对治疗有反应的患者将继续服用药物/安慰剂 12 周,并在第 14 周、第 18 周和第 22 周进行评估评估将重点关注创伤后应激障碍 (PTSD) 症状、一般功能、人际关系问题以及共病焦虑和抑郁症状。
这项研究有几个优点。它研究了两种具有成本效益、经过验证的补充疗法在患有慢性创伤后应激障碍(PTSD)的新人群(大规模恐怖袭击的受害者)中的组合。然后,它会检查在维护阶段是否仍然存在甚至继续产生效益。通过研究这种严重且常见的精神疾病的治疗反应最大化,研究结果可能会增强公众健康。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial.
- DOI:10.1176/appi.ajp.2011.11020321
- 发表时间:2012-01
- 期刊:
- 影响因子:0
- 作者:Schneier FR;Neria Y;Pavlicova M;Hembree E;Suh EJ;Amsel L;Marshall RD
- 通讯作者:Marshall RD
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Franklin R. Schneier其他文献
Franklin R. Schneier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Franklin R. Schneier', 18)}}的其他基金
Targeting Dopamine-Mediated Social Reward Sensitivity to Remediate Social Disconnection
针对多巴胺介导的社会奖励敏感性来修复社会脱节
- 批准号:
10572245 - 财政年份:2023
- 资助金额:
$ 43.52万 - 项目类别:
Gaze-contingent music reward therapy for social anxiety
针对社交焦虑的注视相关音乐奖励疗法
- 批准号:
10624779 - 财政年份:2018
- 资助金额:
$ 43.52万 - 项目类别:
Gaze-contingent music reward therapy for social anxiety
针对社交焦虑的注视相关音乐奖励疗法
- 批准号:
10392334 - 财政年份:2018
- 资助金额:
$ 43.52万 - 项目类别:
Ventrostriatal Dopamine Release and Reward Motivation in MDD
MDD 中的腹纹状体多巴胺释放和奖励动机
- 批准号:
8891167 - 财政年份:2014
- 资助金额:
$ 43.52万 - 项目类别:
Ventrostriatal Dopamine Release and Reward Motivation in MDD
MDD 中的腹纹状体多巴胺释放和奖励动机
- 批准号:
8579490 - 财政年份:2013
- 资助金额:
$ 43.52万 - 项目类别:
Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
米氮平和 SSRI 联合治疗 PTSD:安慰剂对照试验
- 批准号:
7978835 - 财政年份:2010
- 资助金额:
$ 43.52万 - 项目类别:
Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
米氮平和 SSRI 联合治疗 PTSD:安慰剂对照试验
- 批准号:
8254449 - 财政年份:2010
- 资助金额:
$ 43.52万 - 项目类别:
Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
米氮平和 SSRI 联合治疗 PTSD:安慰剂对照试验
- 批准号:
8103124 - 财政年份:2010
- 资助金额:
$ 43.52万 - 项目类别:
Neural circuitry of submissive behavior and treatment response in social anxiety
社交焦虑中顺从行为和治疗反应的神经回路
- 批准号:
7256857 - 财政年份:2007
- 资助金额:
$ 43.52万 - 项目类别:
Neural circuitry of submissive behavior and treatment response in social anxiety
社交焦虑中顺从行为和治疗反应的神经回路
- 批准号:
7394457 - 财政年份:2007
- 资助金额:
$ 43.52万 - 项目类别:
相似国自然基金
去泛素化酶USP5调控P53通路在伴E2A-PBX1成人ALL的致病机制研究
- 批准号:81900151
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
核基质结合区蛋白SATB1调控CCR7抑制急性T淋巴细胞白血病中枢浸润的作用与机制
- 批准号:81870113
- 批准年份:2018
- 资助金额:55.0 万元
- 项目类别:面上项目
成人及儿童急性淋巴细胞白血病的基因组转录组生物信息学分析方法建立及数据分析
- 批准号:81570122
- 批准年份:2015
- 资助金额:60.0 万元
- 项目类别:面上项目
NR3C1基因突变在成人急性淋巴细胞白血病耐药与复发中的作用与机制研究
- 批准号:81470309
- 批准年份:2014
- 资助金额:75.0 万元
- 项目类别:面上项目
儿童和成人急性T淋巴细胞白血病中miRNA和转录因子共调控网络的差异性研究
- 批准号:31270885
- 批准年份:2012
- 资助金额:80.0 万元
- 项目类别:面上项目
相似海外基金
Stress experiences as markers of person-level vulnerability and temporal risk for near-term suicidal ideation
压力体验是个人脆弱性和近期自杀意念暂时风险的标志
- 批准号:
10825847 - 财政年份:2023
- 资助金额:
$ 43.52万 - 项目类别:
Molecular target and circuitry underlying the preclinical effects of psychedelics in models of opioid use disorder
阿片类药物使用障碍模型中迷幻药临床前作用的分子靶点和电路
- 批准号:
10751173 - 财政年份:2023
- 资助金额:
$ 43.52万 - 项目类别:
IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies
抑制 IgE 的小檗碱纳米药物治疗食物过敏
- 批准号:
10698900 - 财政年份:2023
- 资助金额:
$ 43.52万 - 项目类别:
An Enzyme-Based Antidote for Acute Nicotine Toxicity
一种基于酶的急性尼古丁中毒解毒剂
- 批准号:
10790758 - 财政年份:2023
- 资助金额:
$ 43.52万 - 项目类别:
Novel behavioral screening tool for therapeutics against organophosphorus agents
用于有机磷药物治疗的新型行为筛选工具
- 批准号:
10631009 - 财政年份:2023
- 资助金额:
$ 43.52万 - 项目类别: